Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

colistimethate

- PMLiVE

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Alzheimer's patients typically experience poor sleep

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Onyx Health

- PMLiVE

Integrating electronic health records into clinical trials

How organisations are working to realise the research potential of EHRs

- PMLiVE

Keytruda claims first place in bladder cancer race

Stays ahead of rivals in the PD-1/PD-L1 inhibitor class

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

FDA follows EMA with approval of Merck’s Ebola vaccine

First to be approved in the US

- PMLiVE

FDA panel clears Keytruda for hard-to-treat bladder cancer

New treatment option for high-risk patients

- PMLiVE

Novel endpoints in the digital age

Redesigning the goalposts

- PMLiVE

Intec battered as Novartis ducks out of Accordion collaboration

Shares fell by more than 12% after the annoucement

- PMLiVE

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Deal due to close in the first quarter of 2020

- PMLiVE

Five key trends in precision and personalised healthcare

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links